NCT07583121Not yet recruiting
Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Skin Microbiota
Impact of a Daily Application of an Omega-3 Monoglycerides Based Serum and Cream on the Ratio of 4 Bacteria of the Skin Microbiota (Staphylococcus Aureus, Staphylococcus Epidermis, Cutibacterium Acnes and Streptococcus Pyogenes). Exploratory Study (COS-PBP-03).
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
This exploratory study aims to investigate the prebiotic potential of daily application of an omega-3 serum and cream to skin affected by eczema. The study will also collect data on any potential adverse effects of the products. Ten subjects will be enrolled in the study and will receive the same treatment for fourteen days. Their baseline condition before treatment will serve as a control for the effects observed after treatment on the targeted eczema area. A second area of eczema treated with the patient's usual skincare routine will also serve as a control.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 23 Apr 2026
- Start date
- 4 May 2026
- Primary completion date
- 4 Dec 2026
- Lead sponsor
- SCF Pharma
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07583121
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 4 May 2026 to the primary completion date, 4 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Participant aged of at least 18 years old.
- Participant diagnosed with eczema who did not use corticosteroids in the 14 days prior to study day 1;
- Available for the entire duration of the study and willing to participate based on the information provided in the ICF duly read and signed by the latter.
- Participant without intellectual problems likely to limit the validity of consent to participate in the study and compliance with protocol requirements, having the ability to cooperate adequately, understand and observe the instructions of research staff
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SCF Pharma Coordinator of this site? Confirm its status | Rimouski | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.